scholarly journals Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease

2016 ◽  
Vol 240 (4) ◽  
pp. 277-279 ◽  
Author(s):  
Tomohiro Kurokawa ◽  
Soichiro Murata ◽  
Nobuhiro Ohkohchi
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Receptor Agonist ◽  
Chronic Liver ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Term Administration

Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia

2019 ◽  
Vol 38 (4) ◽  
pp. 329-334 ◽  
Author(s):  
Yuki Tsuji ◽  
Hideto Kawaratani ◽  
Koji Ishida ◽  
Daisuke Kaya ◽  
Takuya Kubo ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Platelet Count ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Small Molecule ◽  
Receptor Agonist ◽  
Common Complication ◽  
Platelet Counts ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist

Aims: Thrombocytopenia is a common complication among patients with chronic liver disease (CLD). To increase platelet counts, lusutrombopag, a small-molecule, second-generation thrombopoietin receptor agonist, was developed in September 2015. Lusutrombopag is mainly used in patients with platelet counts <50,000/µL. However, its usefulness in patients with platelet counts ≥50,000/µL remains unknown. We studied the effectiveness of lusutrombopag administration in patients with platelet counts of ≥50,000/µL. Methods: We evaluated 36 patients who received lusutrombopag for CLD. Changes in platelet counts were evaluated. A treatment response was defined as an increasing platelet count ≥20,000/µL from baseline after drug administration. The differences related to these changes between platelet counts ≥50,000 and <50,000/µL were evaluated. Results: Of the patients, 25 had platelet counts ≥50,000/µL. The increase in platelet count and the date in which it reached a maximum did not significantly differ between the groups. The effectiveness of lusutrombopag did not significantly differ between the groups. In both groups, no adverse reaction was observed during lusutrombopag administration. Conclusion: In this study, we showed the effectiveness of lusutrombopag, which had no complications. This study is the first to report that the effectiveness of lusutrombopag was the same for patients with platelet counts ≥50,000/µL and <50,000/µL.

scholarly journals Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 863-866
Author(s):  
Sabah E. Mohamed ◽  
Mohamed A. Yassin
Keyword(s):  
Liver Disease ◽  
Drug Use ◽  
Portal Vein ◽  
Chronic Liver Disease ◽  
Portal Vein Thrombosis ◽  
Receptor Agonist ◽  
Off Label ◽  
Vein Thrombosis ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist

Off-label drug use refers to drug use beyond the specifications authorized for marketing [J Med Case Rep. 2014 Dec;8(1):303]. Eltrombopag is a thrombopoietin receptor agonist that has been used in treating thrombocytopenia due to chronic liver disease (CLD) as an off-label medication. Treatment of thrombocytopenia in patients with CLD constitute a real dilemma as the options are limited and some of them are invasive. However, thrombopoietin receptor agonist has been increasingly used for this purpose. Here we report a 34-year-old woman who has been diagnosed with CLD due to autoimmune hepatitis 20 years ago. Her condition was complicated with portal vein thrombosis, chronic thrombocytopenia, and variceal hemorrhage, and she has been listed as a candidate for liver transplantation. Given her high risk of bleeding, we started her on low dose of eltrombopag (25 mg daily) in order to maintain a platelet level of ≥50 × 103/µL. However, 1 year after initiation of the therapy, she developed left lower limb deep vein thrombosis.

Hypermanganesemia in Long-Term Intravenous Nutrition and Chronic Liver Disease

1999 ◽  
Vol 23 (6) ◽  
pp. 350-355 ◽  
Author(s):  
Catherine A. Wardle ◽  
Alastair Forbes ◽  
Norman B. Roberts ◽  
A.V. Jawhari ◽  
Alan Shenkin
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Intravenous Nutrition
Sign in / Sign up

Export Citation Format

Share Document